MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why NMTC Stock surged +12.96% Today — RQD Quant Desk Flash
$0.97 +12.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.99
NeuroOne Medical Technologies Corporation (NMTC) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $8.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.99 (+2.14%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NMTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY NMTC SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (29% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$1.12-14.3% Next Q
57
Q2 (-2Q)Grade C-$0.96-4.2% Next Q
54
Q3 (-1Q)Grade C-$0.92+5.4% Next Q
52
CurrentGrade D$0.97-5.4% Hist 90D α
49
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NMTC Turnaround Squeeze
While NMTC currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($1.02) forces dealer call-delta covering toward $6.43.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NMTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NMTC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NMTC Stock surged +12.96% Today — RQD Quant Desk Flash
NeuroOne Medical Technologies Corporation (NMTC) surged +12.96% to $0.97, trading at 4% of its 52-week range ($0.77 – $6.12). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($0.77 – $6.12) with RSI-14 at 40.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.97 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 56.5% gross margin and $0 annual free cash flow.
Live NMTC Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NMTC)
- ✓Walkthrough of NMTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NMTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.36%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.97H $1.02L $0.87C $0.97VOL 33.8K
RES: $2.67SUP: $0.72SMA50: $1.32SMA200: $3.20
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NMTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +163.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NMTC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NMTC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NMTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NMTC)
Health Care Rank #371 of 1016
⚔️ AEMD vs NMTC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NMTC vs. AEMD, PLSM, FEMY, ICU)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroOne Medical Technologies Corporation (NMTC) ranks #371 by composite RQD confidence (49/100, grade D) and #905 by equity capitalization ($8.8M). Within this direct 5-issuer industry benchmark cohort, NMTC leads on earnings valuation at N/A trailing P/E, while NMTC leads on capital efficiency and profitability with -35.0% ROIC and 56.5% gross margin. NMTC currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NMTC
ACTIVE
NeuroOne Medical Technologies Corporation | D | 49/100 | — | 56.5% | -35.0% | +12.96% | $8.8M | Benchmark Subject |
| AEMD Aethlon Medical Inc. | D | 44/100 | — | — | -35.0% | -0.54% | $8.9M | /aemd-vs-nmtc → |
| PLSM Pulsenmore Ltd. | D | 48/100 | — | — | — | -8.48% | $10.5M | /plsm-vs-nmtc → |
| FEMY Femasys Inc. | D- | 35/100 | — | 62.0% | -35.0% | -3.90% | $11.3M | /femy-vs-nmtc → |
| ICU SeaStar Medical Holding Corporation | E | 33/100 | — | 95.7% | -35.0% | -6.85% | $12.2M | /icu-vs-nmtc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001500198In its most recent audited fiscal period (FY2025, filed 2025-09-30), NeuroOne Medical Technologies Corporation (NMTC) reported GAAP revenue of $9.1M (+163.5% vs. FY2024 revenue of $3.5M , and +366.0% cumulative change since FY2023) , GAAP net income of -$3.6M, operating cash flow of -$2.8M, and free cash flow of -$2.9M (+73.8% YoY). On the balance sheet, NMTC closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $9.1M | -$3.6M | -$2.8M | -$2.9M | $8.6M | — |
| FY2024 (FY) | 2024-09-30 | $3.5M | -$12.3M | -$11.0M | -$11.1M | $6.5M | — |
| FY2023 (FY) | 2023-09-30 | $2.0M | -$11.9M | -$12.9M | -$12.9M | — | — |
3. NMTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NMTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.97 (+12.96% 1D, market cap $8.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMTC ranks #371 in composite RQD confidence.
How does NMTC compare to AEMD and PLSM in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M) and PLSM (Pulsenmore Ltd.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $10.5M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NMTC?
Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NMTC trading relative to its 50-day, 200-day, and 52-week technical levels?
NMTC last traded at $0.97 (+12.96% on volume of 66,810 shares), positioning the stock -26.52% below its 50-day simple moving average ($1.32) and -69.69% below its 200-day simple moving average ($3.20). Across its 52-week range of $0.77 to $6.12, NMTC sits at the 3.7% percentile with a 14-day RSI of 40.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.09).
NMTC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NMTC stock moving today?
Why NMTC Stock surged +12.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.